

Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026

<https://marketpublishers.com/r/P407D8D33104EN.html>

Date: December 2021

Pages: 95

Price: US\$ 4,950.00 (Single User License)

ID: P407D8D33104EN

Abstracts

The global prostate health market is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period. The prostate gland (the prostate) is an organ of the male reproductive system. The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer. Benign prostatic hyperplasia (BPH) is defined as a medical condition affecting men. It involves the non-cancerous enlargement of the prostate gland. While BPH rarely shows symptoms before the age of 40, the risk of contracting BPH increases with age. The condition affects nearly 50% of men between the ages of 51 and 60 and up to 90% of men older than 80. Treatment measures such as medications and surgery have been used for patients with BPH.

Prostate Cancer to hold the largest segment of the market

Based on disease indication, the prostate health market is segmented into prostate cancer, benign prostate hyperplasia, and prostatitis. In 2020, prostate cancer accounted for the largest share in the prostate health market. Typically, hormone therapy is considered an effective option as the first line of treatment for prostate cancer. Cancer vaccines, radiopharmaceutical agents, secondary hormone therapies, or chemotherapies follow hormonal therapy as treatment options. Cancerous cells are found to be developing a resistance to these therapies after some months, as a result of which immunotherapies are expected to be adopted widely for the treatment of prostate

cancer in the near future.

The US to dominate the prostate health market in North America

The prostate health market is segmented into five six regions—North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has been among the frontrunners in developing prostate health therapies in the healthcare industry. The market growth in the US (a major contributor to the North American prostate health market) can be mainly attributed to the growing target population, the high incidence of BPH, prostate cancer, and prostatitis, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong healthcare infrastructure, research funding, and product launches have accelerated the growth of this market.

Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35% • By Designation: Director-level – 30%, C-level – 20%, and Others – 50% • By Region: North America - 33%, Europe – 24%, APAC – 27%, Rest of the World – 16%

Some of the prominent players operating in the prostate health market are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan) and other players.

Research Coverage

This report studies the prostate health market based on type, mode of purchase, and application, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to two main geographies – source and destination.

Key Benefits of Buying the Report

This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new

entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
- 1.3 MARKET SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 STAKEHOLDERS
- 1.6 LIMITATIONS OF THE CURRENT EDITION OF THE REPORT

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - FIGURE 1 RESEARCH DESIGN
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Key data from secondary sources
 - 2.1.2 PRIMARY DATA
 - FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 - 2.1.2.1 Key data from primary sources
- 2.2 MARKET SIZE ESTIMATION
 - FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
 - 2.2.1 BOTTOM-UP APPROACH
 - 2.2.2 GROWTH FORECAST
 - 2.2.3 TOP-DOWN APPROACH
 - FIGURE 4 PROSTATE HEALTH MARKET: TOP-DOWN APPROACH
- 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
 - FIGURE 5 DATA TRIANGULATION METHODOLOGY
- 2.4 ASSUMPTIONS FOR THE STUDY

3 MARKET DYNAMICS

- 3.1 MARKET DYNAMICS
 - FIGURE 6 PROSTATE HEALTH MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

3.1.1 DRIVERS

3.1.1.1 Increasing prevalence of benign prostatic hyperplasia

FIGURE 7 SHARE OF THE MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019)

3.1.1.2 Increasing obesity

3.1.1.3 Investments, funds, and grants for research in BPH treatment

3.1.1.4 Rising prevalence of prostate cancer

3.1.1.5 Increasing demand for hormone therapy drugs

3.1.1.6 Emerging therapies for prostate cancer

TABLE 1 SELECT THERAPIES IN THE PHASE III PIPELINE FOR PROSTATE CANCER

3.1.2 RESTRAINTS

3.1.2.1 Side-effects associated with BPH medications

TABLE 2 SIDE-EFFECTS OF BPH DRUGS

3.1.3 OPPORTUNITIES

3.1.3.1 Emerging markets

3.1.3.2 Promising product pipeline

TABLE 3 PIPELINE DRUGS

3.1.4 CHALLENGES

3.1.4.1 Low awareness regarding prostate health among men

3.1.4.2 Product recalls in the prostate health market

TABLE 4 PRODUCT RECALLS IN THE PROSTATE HEALTH MARKET

4 PROSTATE HEALTH MARKET, BY DISEASE TYPE

4.1 INTRODUCTION

TABLE 5 PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

4.2 PROSTATE CANCER

TABLE 6 PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 7 PROSTATE CANCER MARKET, BY REGION, 2018–2026 (USD MILLION)

4.2.1 AR-DIRECTED THERAPIES

4.2.1.1 AR-directed therapies are expected to remain the dominant drug class for the treatment of prostate cancer

TABLE 8 AR-DIRECTED THERAPIES MARKET, BY REGION, 2018–2026 (USD MILLION)

4.2.2 HORMONE ADT

4.2.2.1 ADT is the most common form of hormonal treatment

TABLE 9 HORMONAL ADT MARKET, BY REGION, 2018–2026 (USD MILLION)

4.2.3 CYTOTOXIC AGENTS

4.2.3.1 Newer cytotoxic agents are being studied in prostate cancer with the goal of achieving FDA approvals

TABLE 10 CYTOTOXIC AGENTS MARKET, BY REGION, 2018–2026 (USD MILLION)

4.2.4 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS

4.2.4.1 PARP inhibitors are expected to be the leading drug class for the treatment of prostate cancer

TABLE 11 PARP INHIBITORS MARKET, BY REGION, 2018–2026 (USD MILLION)

4.2.5 OTHER THERAPIES

TABLE 12 OTHER THERAPIES MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3 BENIGN PROSTATIC HYPERPLASIA

TABLE 13 BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 14 BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3.1 ALPHA BLOCKERS

TABLE 15 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 16 BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION, 2018–2026 (USD MILLION)

4.3.1.1 Tamsulosin

4.3.1.1.1 Tamsulosin has been prescribed for BPH since 2000

TABLE 17 TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3.1.2 Silodosin

4.3.1.2.1 Benefits of silodosin and the launch of generics to support market growth

TABLE 18 SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3.1.3 Alfuzosin

4.3.1.3.1 Side-effects and fewer generic launches have hindered market growth to some extent

TABLE 19 ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3.1.4 Doxazosin

4.3.1.4.1 Doxazosin was introduced in 2005 and has seen many generic launches since

TABLE 20 DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3.1.5 Other alpha blockers

TABLE 21 OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3.2 5-ALPHA REDUCTASE INHIBITORS

TABLE 22 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026

(USD MILLION)

TABLE 23 BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018–2026

(USD MILLION)

4.3.2.1 Dutasteride

4.3.2.1.1 Availability of generics post-patent expiry to support market growth

TABLE 24 DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3.2.2 Finasteride

4.3.2.2.1 Finasteride is less effective than alpha blockers in improving LUTS

TABLE 25 FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)

4.3.3 OTHER DRUG CLASSES

TABLE 26 OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018–2026 (USD MILLION)

4.4 PROSTATITIS

TABLE 27 PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 28 PROSTATITIS MARKET, BY REGION, 2018–2026 (USD MILLION)

4.4.1 PRESCRIPTION PRODUCTS

4.4.1.1 Prescription drugs account for the larger share of the products used for the treatment of prostatitis

TABLE 29 PRESCRIPTION PRODUCTS MARKET, BY REGION, 2018–2026 (USD MILLION)

4.4.2 OVER-THE-COUNTER PRODUCTS

4.4.2.1 Sales of OTC products have risen over the past few years

TABLE 30 OVER-THE-COUNTER PRODUCTS MARKET, BY REGION, 2018–2026 (USD MILLION)

5 PROSTATE HEALTH MARKET, BY REGION

5.1 INTRODUCTION

TABLE 31 PROSTATE HEALTH MARKET, BY REGION, 2018–2026 (USD MILLION)

5.2 NORTH AMERICA

TABLE 32 NORTH AMERICA: PROSTATE HEALTH MARKET, BY COUNTRY, 2018–2026 (USD MILLION)

TABLE 33 NORTH AMERICA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 34 NORTH AMERICA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 35 NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 36 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA

BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 37 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 38 NORTH AMERICA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.2.1 US

5.2.1.1 The US holds the largest share of the North American market

TABLE 39 US: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 40 US: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 41 US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 42 US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 43 US: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 44 US: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.2.2 CANADA

5.2.2.1 Rising geriatric population and product approvals to support market growth

TABLE 45 CANADA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 46 CANADA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 47 CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 48 CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 49 CANADA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 50 CANADA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.3 EUROPE

TABLE 51 EUROPE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 52 EUROPE: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 53 EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 54 EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 55 EUROPE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 56 EUROPE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 57 EUROPE: PROSTATE HEALTH MARKET, BY COUNTRY, 2018–2026 (USD MILLION)

5.3.1 GERMANY

5.3.1.1 Increasing healthcare expenditure to support German market growth

TABLE 58 GERMANY: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 59 GERMANY: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 60 GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 61 GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 62 GERMANY: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 63 GERMANY: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.3.2 UK

5.3.2.1 Availability of innovative treatment options to drive the market in the UK

TABLE 64 UK: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 65 UK: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 66 UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 67 UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 68 UK: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 69 UK: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.3.3 FRANCE

5.3.3.1 Rising geriatric population to accelerate the growth of the market

TABLE 70 FRANCE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026

(USD MILLION)

TABLE 71 FRANCE: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026

(USD MILLION)

TABLE 72 FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026

(USD MILLION)

TABLE 73 FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 74 FRANCE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 75 FRANCE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.3.4 REST OF EUROPE

TABLE 76 ROE: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 77 ROE: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 78 ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 79 ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 80 ROE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 81 ROE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.4 ASIA PACIFIC

TABLE 82 ASIA PACIFIC: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 83 ASIA PACIFIC: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 84 ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 85 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 86 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 87 ASIA PACIFIC: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 88 ASIA PACIFIC: PROSTATE HEALTH MARKET, BY COUNTRY, 2018–2026 (USD MILLION)

5.4.1 JAPAN

5.4.1.1 Japan holds the largest share of the APAC market

TABLE 89 JAPAN: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 90 JAPAN: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 91 JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 92 JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 93 JAPAN: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 94 JAPAN: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.4.2 CHINA

5.4.2.1 Increasing obese population to support market growth

TABLE 95 CHINA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 96 CHINA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 97 CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 98 CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 99 CHINA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 100 CHINA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.4.3 INDIA

5.4.3.1 Rising prevalence of obesity to accelerate market growth in India

TABLE 101 INDIA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 102 INDIA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 103 INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 104 INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 105 INDIA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 106 INDIA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.4.4 REST OF ASIA PACIFIC

TABLE 107 ROAPAC: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 108 ROAPAC: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 109 ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 110 ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 111 ROAPAC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 112 ROAPAC: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.5 LATIN AMERICA

5.5.1 LATAM MARKETS DRIVEN BY GROWING PATIENT BASE

TABLE 113 LATAM: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 114 LATAM: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 115 LATAM: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 116 LATAM: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 117 LATAM: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 118 LATAM: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

5.6 MIDDLE EAST AND AFRICA

5.6.1 MEA COUNTRIES HOLD SMALLEST SHARE OF GLOBAL MARKET

TABLE 119 MEA: PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)

TABLE 120 MEA: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

TABLE 121 MEA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)

TABLE 122 MEA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 123 MEA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)

TABLE 124 MEA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)

6 COMPETITIVE LANDSCAPE

6.1 OVERVIEW

6.2 REVENUE ANALYSIS OF BPH TREATMENT MARKET

6.2.1 BPH MARKET REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS
FIGURE 8 TOP 5 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS

6.3 REVENUE ANALYSIS OF PROSTATE CANCER THERAPEUTICS MARKET

6.3.1 PROSTATE CANCER THERAPEUTICS REVENUE ANALYSIS OF TOP 5 MARKET PLAYERS

FIGURE 9 TOP 4 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS

6.4 MARKET SHARE ANALYSIS, 2020

6.4.1 PROSTATE HEALTH MARKET SHARE ANALYSIS, 2020

FIGURE 10 PROSTATE HEALTH MARKET SHARE ANALYSIS, 2019

6.5 COMPANY EVALUATION MATRIX

6.5.1 STARS

6.5.2 EMERGING LEADERS

6.5.3 PERVASIVE COMPANIES

6.5.4 PARTICIPANTS

FIGURE 11 PROSTATE HEALTH MARKET: COMPANY EVALUATION MATRIX, 2020

7 COMPANY PROFILES

7.1 GLAXOSMITHKLINE

7.2 ASTELLAS PHARMA

7.3 MERCK

7.4 ELI LILLY AND COMPANY

7.5 ABBOTT LABORATORIES

7.6 JOHNSON & JOHNSON SERVICES, INC.

7.7 ABBVIE

7.8 ASTRAZENECA

7.9 SANOFI

7.10 PFIZER, INC.

8 APPENDIX

8.1 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

8.2 AVAILABLE CUSTOMIZATIONS

8.3 AUTHOR DETAILS

I would like to order

Product name: Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026

Product link: <https://marketpublishers.com/r/P407D8D33104EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P407D8D33104EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970